SZN-413 / Surrozen, Boehringer Ingelheim - LARVOL DELTA

In March 2026, Boehringer Ingelheim achieved a research milestone under the agreement for SZN-413, reflecting a positive outcome of the IND-enabling GLP toxicology study. (GlobeNewswire) - "The Company received a $5.0 million payment from Boehringer Ingelheim in April 2026."

Licensing / partnership • Preclinical • Retinal Disorders

Erratum in: SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy. (PubMed, Transl Vis Sci Technol) - No abstract available

Journal • Diabetic Retinopathy • Retinal Disorders

"$SRZN Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy https://t.co/eUGS1bn09b" (,@stock_titan)

Preclinical • Diabetic Retinopathy • Retinal Disorders

SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy. (PubMed, Transl Vis Sci Technol) - "Reduction of neovascular tufts and avascular areas and of VEGF-driven retinal vascular leakage suggests that SZN-413 can simultaneously address retinal non-perfusion and vascular leakage. FZD4 signaling modulation by SZN-413 is a novel mechanism of action that can offer a new therapeutic strategy for diabetic retinopathy."

Journal • Diabetic Retinopathy • Dyslipidemia • Retinal Disorders

SZN-413, a monospecific Fzd4 Agonist as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy (ARVO 2022) - "The novel Norrin mimetic, SZN-413, demonstrated anti-NV properties and reduced the avascular area in OIR mice, and reduced VEGF-driven retinal vascular leakage in rabbits. The results strongly suggests that the pathological cellular responses can be modulated by SZN-413, with possible therapeutic implications for diabetic retinopathy."

Diabetic Retinopathy • Ophthalmology • Retinal Disorders